Emmanuel Deshayes

University of Montpellier

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (8)

George Coukos

Nicolas MASURIER

Professeur de Chimie Thérapeutique

Université de Montpellier Faculté de Pharmacie

Philippe Pourquier

University of Montpellier

Matthieu Gracia

Sophie Poty

Junior Professor (Chaire Professeur Junior)

Université Bourgogne Europe

Mohamed bouattour

Head of Unit

Manuel BARDIES

Cyril FERSING

Teaching hospital assistant lecturer

Institut des Biomolécules Max Mousseron

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emmanuel Deshayes

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (8)

George Coukos

Nicolas MASURIER

Philippe Pourquier

Matthieu Gracia

Sophie Poty

Mohamed bouattour

Manuel BARDIES

Cyril FERSING

Make your next move.

Emmanuel Deshayes

Research Interests

Explore related searches

Contact this professor

Articles (20)

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

Methodology for comparing absorbed dose rate calculation algorithms in molecular radiotherapy dosimetry

Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy

Prognostic Value of<sup>18</sup>F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE

LYMPHOSCORE (Lymphoscintigraphy Scoring Reliability) Reliability of a New Qualitative and Semiquantitative Lymphoscintigraphy Scoring System for Primary Lymphedema.

Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices

225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer

Fc-engineered monoclonal antibodies to reduce off-target liver uptake

Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool?

Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration

177Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods

Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)

Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease

Collaborators (8)

George Coukos

Nicolas MASURIER

Philippe Pourquier

Matthieu Gracia

Sophie Poty

Mohamed bouattour

Manuel BARDIES

Cyril FERSING

Make your next move.